Results 201 to 210 of about 119,169 (307)

CTLA-4 haploinsufficiency presenting with chronic myeloid leukemia, bullous pemphigoid, and PLA2R-positive membranous nephropathy: a case report. [PDF]

Allergy Asthma Clin Immunol
Deeb N, Deeb S, Ahmed FS, Amro YMY, Altell A, Khalili A.   +5 more
europepmc   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update. [PDF]

Front Immunol
Park J, Skålhegg BS.
europepmc   +1 more source

Advancements in Inorganic Chiral Nanomaterials for Anti‐Tumor Immunotherapy

Cancer Science, EarlyView.
Schematic illustration of how inorganic chiral nanomaterials enhance immune activation to promote tumor cell elimination through targeted delivery, immunogenic cell death, and immune microenvironment modulation. ABSTRACT While the past decade has witnessed unprecedented technological advancements, cancer remains a major health threat, with conventional
Siyu Chen, Qian Tang, Xiqian Chen, Yinghao Liang, Jin Qiu, Yongmei Liao, Changqiang Li, Hongru Yu, Fang Xie, Zongjunlin Liu   +9 more
wiley   +1 more source

CTLA-4-two pathways to anti-tumour immunity? [PDF]

Immunother Adv
Ward FJ, Kennedy PT, Al-Fatyan F, Dahal LN, Abu-Eid R.   +4 more
europepmc   +1 more source

Macrophages regulate PD-1 and CTLA-4 expression on ILC2s and their responsiveness in the tumor microenvironment. [PDF]

Cell Mol Immunol
Ciancaglini C, Santopolo S, Martini S, Scordamaglia F, Pietropaolo G, Laffranchi M, Sciumè G, Ferlazzo G, Vacca P, Moretta L, Quatrini L.   +10 more
europepmc   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

Integrating CTLA-4 Genetics and Soluble Isoforms for the Stratification of HCV-Related Hepatocellular Carcinoma Risk and Aggressiveness. [PDF]

Int J Mol Sci
Hassan M, El-Maadawy WH, Fahim SA, Youssef SM, Badran OM, Balata M.   +5 more
europepmc   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Gene Therapy and Gene Editing in Type 1 Diabetes: CRISPR‐Based β‐Cell Replacement and Treg Immune Modulation Approaches

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease marked by the destruction of pancreatic β‐cells, resulting in lifelong dependence on exogenous insulin. Despite advances in insulin delivery and glucose monitoring technologies, patients remain at risk for acute and long‐term complications, underscoring the need for ...
Tzu‐Min Lin, Hui‐Fang Chang, Tzu‐Ching Lin, Cheng‐Han Lin, Yu‐Ling Sun, Chih‐Sheng Lin   +5 more
wiley   +1 more source